AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04412330 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ICU Recovery + Physical Therapy
Description: Physical therapy interventions will be supervised by a physical therapist (>20 years of experience in ICU and pulmonary rehabilitation). Potential interventions include endurance/aerobic training (treadmill training, upper and lower extremity ergometer, and recumbent step machine), upper and lower extremity resistance strength training, balance training, functional movement training, and education. If the interventions are providing in the home environment the exercises will be completed through Zoom, video communications app. Home-based interventions will include seated and standing exercise including resistance exercises (such as lifting small weights) and endurance (e.g. marching or stepping in place, repetitive sit-to-stand training). Physical therapist will provide verbal instructions for motivation and adherence to exercise interventions.
Study NCT03769272 — intervention group
Intervention type: PROCEDURE
Intervention: Measurement of electrical delay during LV lead placement
Description: Measurement of electrical signal in the heart during implantation of CRT, by positioning the lead in different places in the heart.
Study NCT03818516 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral Glucose Tolerance Test (OGTT)
Description: Participants will undergo a fasting blood draw for inflammatory and metabolic markers before a 75gm oral glucose tolerance test (OGTT) and at 1, 2 and 3 hours post-OGTT. Behavioral assessments will also be administered pre- and post-OGTT administration.
Study NCT04037553 — intervention group
Intervention type: OTHER
Intervention: Intracuff pressure measurement
Description: Intracuff pressure values were monitorized and noted before and after head and neck positions and during the surgeries at 15th, 30th, 60th and 90th minutes at related positions and just before extubation at neutral position.
Study NCT01487889 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fatty acid composition of complementary food
Description: Groups receive commercial vegetable-potato-meat-meals as part of complementary food which differs in the fatty acid composition
Study NCT01487889 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fatty acid composition of complementary food
Description: Groups receive commercial vegetable-potato-meat-meals as part of complementary food which differs in the fatty acid composition
Study NCT05929625 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BTL-585-2 RF+US
Description: The subjects of RF+US group will receive four simultaneous RF+US treatments of the entire face area including forehead, upper and lower cheeks and area around eyes.
Study NCT05929625 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BTL-585-2 RF
Description: The subjects of RF only study group will receive four RF treatments of the entire face area including forehead, upper and lower cheeks and area around eyes.
Study NCT01202630 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus acidophilus CL1285® and Lactobacillus casei
Description: 2 capsules of Lactobacillus acidophilus CL1285® and Lactobacillus casei (50 billion cfu/capsule), consumed once daily for 60 days
Study NCT01202630 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 capsules of placebo (no live cells), consumed once daily for 60 days
Study NCT00120965 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AutoPulse
Description: Standard device settings
Study NCT00120965 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual CPR
Description: Manual CPR
Study NCT02799498 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Auto-injector device
Description: Single 50 mg subcutaneous dose of liquid etanercept (ENBREL®) in a 1.0 ml pre-filled syringe administered via an auto-injector device manufactured by Scandinavian Health Limited (SHL)
Study NCT02799498 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Etanercept (ENBREL®) via Manual injection
Description: Single 50 mg subcutaneous dose of liquid etanercept (ENBREL®) in a 1.0 ml pre-filled syringe administered via manual injection (reference treatment) to compare to the auto-injection
Study NCT02799498 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etanercept (ENBREL®)
Description: Single 50 mg subcutaneous dose of liquid etanercept (ENBREL®) in a 1.0 ml pre-filled syringe administered via an auto-injector device manufactured by Scandinavian Health Limited (SHL)
Study NCT02231684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Semaglutide administered subcutaneously (s.c. under the skin) in two out of three different strengths (1mg/mL, 3mg/mL and 10 mg/mL).
Study NCT02231684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Semaglutide administered subcutaneously (s.c. under the skin) in two out of three different strengths (1mg/mL, 3mg/mL and 10 mg/mL) or intravenously (i.v.) (1mg/mL).
Study NCT03240770 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VPro5 device
Description: Use of the VPro5 device for 5 minutes a day
Study NCT03240770 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deviation from Standard Tray Wear Time (14 Days)
Description: Patients reduced Tray Wear Time Interval (14 Days)
Study NCT02762214 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Clermont-Ferrand Uterine Manipulator
Description: Pelvic cytology is obtained before starting surgical procedures (washing number 1).~After tubal coagulation, Clermont-Ferrand Uterine Manipulator is installed inside the uterus. At the end of the hysterectomy, after colporrhaphy, a second cytology is obtained (washing number 2)
Study NCT02762214 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No uterine Manipulator
Description: Pelvic cytology is obtained before starting surgical procedures (washing number 1). None uterine manipulator is used and the cervix is closed with a cross stitch.~Tubal coagulation, At the end of the hysterectomy, after colporrhaphy, a second cytology is obtained (washing number 2)
Study NCT00308971 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alpha, gamma, beta, and delta (mixed) tocopherols
Description: approximately 666 IU daily (1 pill) for 4 months
Study NCT00308971 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: alpha lipoic acid
Description: 600 mg daily (2 pills 300 mg each) for 4 months
Study NCT02452151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab-Biosimilar
Study NCT02452151 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Infliximab-Innovator
Study NCT05037838 — intervention group
Intervention type: PROCEDURE
Intervention: Longitudinal strain obtained thanks to transesophageal ultrasound data recorded during liver transplantation
Description: Longitudinal strain of Left Ventricule and longitudinal strain of Right Ventricule free wall obtained thanks to TransEosophagal Ultrasound performed during the Liver Transplant
Study NCT03305510 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: vitamin D is below 20ng/ml
Study NCT02703636 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Rivastigmine Patch
Description: Alzheimer's disease patient who is applicable to 1 step titration method (initial loading dose is a rivastigmine patch 9.0 mg/day and will be up-titrated after 4 weeks to reach the maintenance dose of 18 mg/day). Rivastigmine patch is a marketed drug, therefore the dose, dose regimen and titration scheme are in accordance with product label.
Study NCT00308971 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo for alpha, gamma, beta, and delta (mixed) tocopherols; 1 pill daily for 4 months
Study NCT01619033 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: BF2.649
Description: single dose 20 mg
Study NCT01619033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BF2.649
Description: single dose 20 mg
Study NCT06381869 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Pea protein (NUTRALYS ® S85 plus) in water
Description: After selection and randomization, the subjects will consume per os Pea protein (NUTRALYS® S85 plus) in water containing 0,41 g of tested protein/kg of body weight.
Study NCT06381869 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Pea protein (NUTRALYS ® S85 plus) within meal
Description: After selection and randomization, the subjects will consume per os Pea protein (NUTRALYS® S85 plus) within a meal containing 0,41 g of tested protein/kg of body weight.
Study NCT06381869 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Whey protein in water
Description: After selection and randomization, the subjects will consume per os whey protein in water containing 0,41 g of tested protein/kg of body weight.
Study NCT02605135 — intervention group
Intervention type: DEVICE
Intervention: Continued Pessary Use
Description: Pessary Fitting
Study NCT00465101 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: GreenLight HPS
Description: Greenlight HPS laser system for treatment of BPH
Study NCT06381869 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Whey protein within meal
Description: After selection and randomization, the subjects will consume per os whey protein within a meal containing 0,41 g of tested protein/kg of body weight.
Study NCT01494610 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SERETIDE Rotacaps
Description: The study consists of four treatment periods of 10 +/- 1 days each in a cross-over fashion. Each patient will be administered SERETIDE delivered via a capsule-based inhaler (Rotacaps) twice for two treatment periods and a placebo delivered via a capsule-based inhaler (Rotacaps) twice for two treatment periods in a randomised, double-blind, double-dummy fashion. Dosing is twice daily in the morning and evening over the duration of each treatment period.
Study NCT01494610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SERETIDE Rotacaps
Description: The study consists of four treatment periods of 10 +/- 1 days each in a cross-over fashion. Each patient will be administered SERETIDE delivered via a capsule-based inhaler (Rotacaps) twice for two treatment periods and a placebo delivered via a capsule-based inhaler (Rotacaps) twice for two treatment periods in a randomised, double-blind, double-dummy fashion. Dosing is twice daily in the morning and evening over the duration of each treatment period.
Study NCT01494610 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SERETIDE Diskus
Description: The study consists of four treatment periods of 10 +/- 1 days each in a cross-over fashion. Each patient will be administered SERETIDE delivered via a multi-dose dry powder inhaler (Diskus) twice for two treatment periods and a placebo delivered via a multi-dose dry powder inhaler (Diskus) twice for two treatment periods in a randomised, double-blind, double-dummy fashion. Dosing is twice daily in the morning and evening over the duration of each treatment period.
Study NCT01494610 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SERETIDE Diskus
Description: The study consists of four treatment periods of 10 +/- 1 days each in a cross-over fashion. Each patient will be administered SERETIDE delivered via a multi-dose dry powder inhaler (Diskus) twice for two treatment periods and a placebo delivered via a multi-dose dry powder inhaler (Diskus) twice for two treatment periods in a randomised, double-blind, double-dummy fashion. Dosing is twice daily in the morning and evening over the duration of each treatment period.
Study NCT00651027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-868554
Description: 200 mg, Child-Pugh Class A
Study NCT00651027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-868554
Description: 200 mg, Child-Pugh Class B
Study NCT00651027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-868554
Description: 200 mg, healthy volunteers
Study NCT02263066 — intervention group
Intervention type: BIOLOGICAL
Intervention: BAY14-2222_Kogenate-FS FVIII
Description: Depends on Doctor's decision
Study NCT03063996 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: peripheral IV access procedure
Description: standard of care guided IV access into peripheral vein excluding IJ
Study NCT03063996 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Peripheral IJ access procedure
Description: standard of care guided IV access into IJ
Study NCT00594464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine
Description: 2 mg/24 h, 4 mg/24 h, 6 mg/24 h and 8 mg/24 h patch;~Single patches and a combination of 2 of these patches for a dosage of up to 16 mg/24 h;~One (1) regimen on day of surgery, but exceptionally extended for up to 2 (two) weeks if the patient requires unexpected ventilation after surgery.
Study NCT03299842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZX008 (Fenfluramine Hydrochloride)
Description: ZX008 is supplied as an oral solution in a concentration of 2.5 mg/mL. Subjects will be titrated to an effective dose beginning with 0.2 mg/kg/day (maximum: 30 mg/day).
Study NCT03525197 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey protein-based supplement
Description: High quality protein supplement to be consumed twice daily
Study NCT03525197 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Collagen protein-based supplement
Description: Lower quality protein supplement to be consumed daily
Study NCT02086929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trazodone
Study NCT02086929 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venlafaxine
Study NCT01893424 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sativex buccal spray
Description: buccal spray
Study NCT01893424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBD-THC-Piperine-PNL capsule
Description: a capsule containing Cannabidiol and Tetrahydrocannabinol combination
Study NCT04734496 — intervention group
Intervention type: OTHER
Intervention: National Healthcare System Standard of care for each disease type (National Institute for Health and Care Excellence guidelines)
Description: National Healthcare System Standard of care for each disease type (National Institute for Health and Care Excellence guidelines)
Study NCT03395314 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: 1 single dose of IV ketamine
Study NCT03395314 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Midazolam
Description: 1 single dose of IV midazolam
Study NCT02385799 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sertraline Liquid Placebo
Description: Liquid placebo given in parallel to active medication
Study NCT02385799 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sertraline
Description: Active medication
Study NCT00308971 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo for alpha lipoic acid; 2 pills daily for 4 months
Study NCT00685113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DR-3001
Description: 4mg/day vaginal ring inserted vaginally and replaced every 4 weeks
Study NCT00685113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DR-3001
Description: 6mg/day vaginal ring inserted vaginally and replaced every 4 weeks
Study NCT01768572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sarilumab SAR153191 (REGN88)
Description: Pharmaceutical form: solution Route of administration: subcutaneous
Study NCT01768572 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tocilizumab
Description: Pharmaceutical form: solution Route of administration: intravenous
Study NCT01768572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydroxychloroquine
Description: Dispensed according to local practice.
Study NCT01768572 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hydroxychloroquine
Description: Dispensed according to local practice.
Study NCT01768572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Dispensed according to local practice.
Study NCT01768572 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate
Description: Dispensed according to local practice.
Study NCT01768572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sulfasalazine
Description: Dispensed according to local practice.
Study NCT01768572 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sulfasalazine
Description: Dispensed according to local practice.
Study NCT01768572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leflunomide
Description: Dispensed according to local practice.
Study NCT01737359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amdoxovir 300 mg bid
Description: 2 x 150 mg capsules bid
Study NCT01737359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amdoxovir 500 mg bid
Description: 2 x 250 mg capsules bid
Study NCT01737359 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tenofovir DF 300 mg qd
Description: 1 x 300 mg tablet once daily
Study NCT04082494 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Music via internet and noise canceling headphones
Description: Optional music via internet and noise canceling headphones will be offered.
Study NCT01768572 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: leflunomide
Description: Dispensed according to local practice.
Study NCT01768572 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: subcutaneous placebo
Description: Pharmaceutical form: solution Route of administration: subcutaneous
Study NCT01768572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravenous placebo
Description: Pharmaceutical form: solution Route of administration: intravenous
Study NCT03503604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 400 mg/m2 bolus followed by a 2400 mg/m2 continuous infusion, every 2 weeks
Study NCT00685113 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo vaginal ring inserted vaginally and replaced every 4 weeks
Study NCT02321553 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brown rice
Description: brown rice cake
Study NCT03503604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: IV Infusion, 85 milligrams per square meter (mg/m2) every 2 weeks
Study NCT04082494 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Beverages
Description: Beverages will be optionally offered (with and without sugar, warm or cold).
Study NCT02259777 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan/Amlodipine
Description: Fixed dose combination tablet
Study NCT02259777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan/Amlodipine
Description: Fixed dose combination tablet
Study NCT02259777 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high fat, high caloric meal
Study NCT03503604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: IV infusion, 400 mg/m2 every 2 weeks
Study NCT00233142 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expressive writing
Description: Writing as therapeutic intervention
Study NCT00233142 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Neutral writing
Description: Non-expressive writing
Study NCT00080119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid (INH)
Description: Antibiotic for the prevention and treatment of TB
Study NCT00080119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimethoprim/Sulfamethoxazole (TMP/SMX)
Description: Antibiotic for the prevention and treatment of pneumocystis pneumonia (PCP)
Study NCT00080119 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isoniazid Placebo (PL)
Description: Isoniazid placebo and TMP/SMX
Study NCT01195402 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pulmonary outpatient rehabilitation
Description: Subjects take part in once weekly training sessions of 60 min duration. Sessions take place in local physiotherapist practice and involve simple training devices (chairs, elastic bands, balls). In addition, subjects take part in a structured and validated educational program concerning COPD (COBRA) of 8 h duration. They are offered counselling regarding nutrition (2 h), psycho-social (2 h) and social (2 h) aspects.
Study NCT00552656 — intervention group
Intervention type: DEVICE
Intervention: Firebird(TM) Sirolimus-Eluting Stent
Description: balloon expandable stent that made of stainless steel.The length is from 13mm-33mm,and the diameter from 2.5mm-4.0mm
Study NCT01211210 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluorouracil
Description: Drug: fluorouracil Given IV continuously Radiation: radiation therapy Given 5 days a week for 5-6 weeks
Study NCT01211210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil, oxaliplatin
Description: Drug: fluorouracil Given IV continuously Drug: oxaliplatin Given IV Radiation: radiation therapy Given 5 days a week for 5-6 weeks
Study NCT01211210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil, oxaliplatin
Description: Drug: fluorouracil Given IV continuously Drug: oxaliplatin Given IV